logiover/clinicaltrials-gov-scraper-sample-data huggingface dataset:
Early Screening of Gestational Diabetes Mellitus and Prospective Cohort Study of Postpartum Follow-up
ClinicalTrials.gov ID: NCT03825926
Organization: Fifth Affiliated Hospital, Sun Yat-Sen University
Status: UNKNOWN
Study type: OBSERVATIONAL
Conditions: Gestational Diabetes Mellitus
Lead sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University (OTHER)
Enrollment: 600 participants
Eligibility: sex FEMALE, minimum age 18 Years, maximum age 50 Years
Accepts healthy volunteers: yes
Start date: 2019-06-01
Completion date: 2025-12-01
Locations:
facility: the Fifth Affiliated Hospital of Sun Yat-sen University of Gynaecology and Obstetrics
city: Zhuhai
state: Guangdong
country: China

Summary:
Extraction of whole blood from 10 to 15ml at 24 weeks before pregnancy test, with a view to early detection of GDM, provides evidence for early intervention to improve maternal pregnancy outcomes and metabolic abnormalities.
Prediction of Cardiovascular Events in Type 2 Diabetic Patients With Coronary Artery Disease- Application of Novel Risk Markers and Technology
Acronym: ARTEMIS
ClinicalTrials.gov ID: NCT01426685
Organization: University of Oulu
Status: UNKNOWN
Study type: OBSERVATIONAL
Conditions: Cardiovascular Risk Assessment
Lead sponsor: University of Oulu (OTHER)
Collaborators: The Finnish Funding Agency for Technology and Innovation
Enrollment: 1880 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 75 Years
Accepts healthy volunteers: no
Start date: 2007-08
Completion date: 2019-06
Locations:
facility: University of Oulu
city: Oulu
country: Finland

Summary:
The study will include 1200 patients with type 2 diabetes and angiographically documented coronary artery disease and 600 matched non-diabetic patients without type 2 diabetes. Extensive traditional and novel risk marker tests are performed for the patients and they will be followed-up for 5 years. Sudden cardiac death is the main outcome measure and various other endpoints are secondary endpoints. As a substudy, 120 diabetic patients and 120 non-diabetic patients will undergo exercise training with home monitoring to assess the effects of exercise training on risk profiles.
A Pilot Study to Evaluate the Safety, Tolerability, and Feasibility of Autologous Anti-CD6 Chimeric Antigen Receptor T Regulatory Cells (CD6-CAR Tregs) in Patients With Stage 3 Type 1 Diabetes
ClinicalTrials.gov ID: NCT07395050
Organization: City of Hope Medical Center
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Phases: EARLY_PHASE1
Conditions: Stage 3 Type 1 Diabetes
Interventions: DRUG: AutoCD6-CAR Treg cells
Lead sponsor: City of Hope Medical Center (OTHER)
Collaborators: National Cancer Institute (NCI)
Enrollment: 6 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 35 Years
Accepts healthy volunteers: no
Start date: 2026-06-01
Completion date: 2026-09-14
Locations:
facility: City of Hope Medical Center
city: Duarte
state: California
country: United States

Summary:
Type 1 diabetes (T1D) is a persistent and gradually increasing genetic autoimmune disease requiring life-long management. The disease commonly impacts children. However, a quarter of cases are diagnosed in adults. The pancreatic islet beta-cells are responsible for producing insulin, a peptide hormone that is involved in the tight regulation of blood glucose levels. In T1D, the beta-cells are mistakenly destroyed by autoreactive T cells resulting in insulin deficiency and an inability to regulate blood glucose levels. The cause for such an autoimmune reaction to beta-cells is under active investigation. T regulatory cells (Tregs), are specialized immune cells that typically act to control your immune system. Tregs can be modified in the laboratory to recognize and deactivate T1D-causing cells. This process is done by inserting a piece of DNA (the molecules inside cells that carry genetic information and pass it from one generation to the next) into the Tregs. A non-infectious virus called a lentivirus will carry the piece of DNA into the cells that were collected from a donor. Tregs are then grown to large numbers in the laboratory and stored for treatment of T1D. It is not known whether these Tregs cells will treat T1D.
Updating pReventive and Treatment guidelinEs for Mild hypOglycemia in Individuals Living With Type 1 Diabetes During the erA of Continuous gLucose Monitoring: The REMODAL Trial
Acronym: REMODAL
ClinicalTrials.gov ID: NCT06683391
Organization: Institut de Recherches Cliniques de Montreal
Status: RECRUITING
Study type: INTERVENTIONAL
Phases: NA
Conditions: Type 1 Diabetes
Interventions: BEHAVIORAL: Oral Carbohydrate (CHO) Administration for Hypoglycemia Prevention and Treatment
Lead sponsor: Institut de Recherches Cliniques de Montreal (OTHER)
Enrollment: 32 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 
Accepts healthy volunteers: no
Start date: 2025-02-06
Completion date: 2027-12-31
Locations:
facility: Institut de recherches cliniques de Montréal
city: Montreal
state: Quebec
country: Canada
facility: Montreal Clinical Research Institute
city: Montreal
state: Quebec
country: Canada

Summary:
The REMODAL trial is a randomized crossover study aiming to update treatment guidelines for mild hypoglycemia in people with Type 1 diabetes using continuous glucose monitoring (CGM) technology. The study will assess whether treating mild hypoglycemia proactively (at a glucose threshold of 5.0 mmol/L) with lower doses of carbohydrate (CHO) is more effective than the traditional reactive approach (treatment at \< 4.0 mmol/L). The goal is to reduce hypoglycemia frequency and improve quality of life, while minimizing caloric intake and rebound hyperglycemia.
Middle Cerebral and Umbilical Arteries Doppler Indices in Pregestational Diabetic Versus Normal Pregnancies and Their Values in Predicting Adverse Neonatal Outcome
ClinicalTrials.gov ID: NCT03915990
Organization: Cairo University
Status: UNKNOWN
Study type: INTERVENTIONAL
Phases: NA
Conditions: Diabetes Mellitus, Type 1
Interventions: DIAGNOSTIC_TEST: umbilical and middle cerebral artery Doppler
Lead sponsor: Cairo University (OTHER)
Enrollment: 120 participants
Eligibility: sex FEMALE, minimum age 18 Years, maximum age 40 Years
Accepts healthy volunteers: no
Start date: 2019-07-01
Completion date: 2020-12
Locations:
facility: kasr elainy hospital (Faculty of Medicine - Cairo University)
city: Cairo
country: Egypt

Summary:
120 patients will be included and divided into two groups; Control group that will include 60 healthy pregnant women and Study group that will include 60 pregestational diabetic pregnant patients which furtherly will be subdivided into two groups according to HbA1C levels namely; controlled diabetics ( will include 30 diabetic pregnant women with controlled DM - HbA1C \< 6.5 %) and uncontrolled diabetics (will include 30 diabetic pregnant women with uncontrolled DM - HbA1C ≥ 6.5 %). Umbilical and middle cerebral arteries Doppler indices (resistance index and pulsatility index) and Cerebroplacental Doppler ratio will be measured for every patient. The recorded neonatal outcomes will include neonatal birth weight, neonatal blood sugar, Apgar score at 1 \& 5 min and neonatal intensive care unit admission.
Effects of Colesevelam HCl On Bile Acid Pools And Kinetic Parameters in Normal Subjects, Subjects With Impaired Glucose Tolerance, And Subjects With Type 2 Diabetes Mellitus
ClinicalTrials.gov ID: NCT00476710
Organization: KineMed
Status: COMPLETED
Study type: OBSERVATIONAL
Conditions: Type 2 Diabetes Mellitus
Impaired Glucose Tolerance
Interventions: DRUG: Colesevelam HCl
Lead sponsor: KineMed (INDUSTRY)
Collaborators: Daiichi Sankyo
University Medical Center Groningen
Diabetes & Glandular Disease Research Associates
Enrollment: 36 participants
Eligibility: sex ALL, minimum age 40 Years, maximum age 60 Years
Accepts healthy volunteers: yes
Start date: 2007-05
Completion date: 2009-04
Locations:
facility: Diabetes & Glandular Disease Research Associates, Inc.
city: San Antonio
state: Texas
country: United States

Summary:
This project will compare the amount of bile acids and their kinetics in overweight and obese people with normal glucose metabolism, impaired glucose tolerance and frank type 2 diabetes. We hypothesize that bile acids will behave differently in these groups. We will also explore the effects of Colesevelam HCl, a medicine that lowers LDL cholesterol by binding bile acids, on bile acids in those groups. We hypothesize the drug may have different actions on bile acids in subjects with different degrees of abnormal glucose metabolism.
Diabetes Prevention in Patients Aged 25-55 From Ethiopian Origin With Prediabetes: Evaluation of Feasibility and Efficacy of Intensive or Less Intensive Lifestyle Intervention
Acronym: DPEP
ClinicalTrials.gov ID: NCT01659697
Organization: Meir Medical Center
Status: UNKNOWN
Study type: OBSERVATIONAL
Conditions: Ethnic Group
Young Adults
Prediabetes
Community Health Services
Interventions: BEHAVIORAL: intensive lifestyle counseling
Lead sponsor: Meir Medical Center (OTHER)
Collaborators: Clalit Health Services
Enrollment: 200 participants
Eligibility: sex ALL, minimum age 25 Years, maximum age 55 Years
Accepts healthy volunteers: no
Start date: 2012-08
Completion date: 2015-07
Locations:
facility: Central district Clalit Health Services
city: Rishon LeZiyyon
country: Israel

Summary:
This study will evaluate the feasibility and efficacy of two interventions of lifestyle ( intensive and less intensive) to prevent diabetes in patients from Ethiopian origin, aged 25 to 55 years old with prediabetes living in Israel and insured by Clalit Health Services in the Central district, using resources existing in this Health Care system (HMO).
A Phase III Study of MP-513 in Combination With Sulfonylurea in Japanese Patients With Type 2 Diabetes Mellitus
ClinicalTrials.gov ID: NCT00974090
Organization: Tanabe Pharma Corporation
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: PHASE3
Conditions: Type 2 Diabetes Mellitus
Interventions: DRUG: Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)
DRUG: Teneli / Teneli + SU
Lead sponsor: Tanabe Pharma Corporation (INDUSTRY)
Enrollment: 194 participants
Eligibility: sex ALL, minimum age 20 Years, maximum age 75 Years
Accepts healthy volunteers: no
Start date: 2009-09
Completion date: 2011-03
Locations:
city: Sapporo
state: Hokkaido
country: Japan

Summary:
The purpose of this study is to evaluate the safety and efficacy of MP-513 (Teneligliptin) in combination with Sulfonylurea in patients with type 2 Diabetes for 12 weeks administration and to evaluate the safety and efficacy of MP-513 in combination with Sulfonylurea with an extension treatment for up to 52 weeks.
A Prospective Trial for Laparoscopic Adjustable Gastric Banding in Morbidly Obese Patients: Report on Weight Loss, Metabolic Changes and Quality of Life
ClinicalTrials.gov ID: NCT01583790
Organization: Assuta Hospital Systems
Status: UNKNOWN
Study type: OBSERVATIONAL
Conditions: Morbid Obesity
Diabetes
Hypertension
Lead sponsor: Assuta Hospital Systems (OTHER)
Enrollment: 2000 participants
Eligibility: sex ALL, minimum age 14 Years, maximum age 65 Years
Accepts healthy volunteers: no
Start date: 2012-01
Completion date: 2020-01
Locations:
facility: Assuta Medical Center
city: Tel Aviv
country: Israel

Summary:
The purpose of this study is to report data with patients after bariatric surgery.
The Effectiveness of CVD Risk Profiles When Used by Allied Health Care Providers (HCP) Within a "Groupe de Médecine de Famille": The Healthy Options Feasibility Study.
ClinicalTrials.gov ID: NCT00746460
Organization: McGill University
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: NA
Conditions: Obesity
Sedentary Lifestyle
Dyslipidemia
Hypertension
Cigarette Smoking
Diabetes
Interventions: BEHAVIORAL: CVD risk profile
Lead sponsor: McGill University (OTHER)
Collaborators: Pfizer
Enrollment: 50 participants
Eligibility: sex ALL, minimum age 30 Years, maximum age 79 Years
Accepts healthy volunteers: no
Start date: 2008-06
Completion date: 2009-10
Locations:
facility: McGill Cardiovascular Health Improvement Program
city: Montreal
state: Quebec
country: Canada

Summary:
The investigators hypothesize that having health care providers other than physicians within a "Groupe de Médecine de Famille" conduct cardiovascular risk assessments and teach lifestyle interventions to primary prevention patients will increase the likelihood that patients will adopt and maintain healthy lifestyles. These objectives will be supported by providing subjects with a cardiovascular risk profile estimating the subject's risk of cardiovascular disease and teaching them how to use the resources related to lifestyle changes available on the www.myhealthcheckup.com Web site.
Targeting Endoplasmic Reticulum Stress to Correct Vascular Insulin Resistance and Glycemic Dysregulation
ClinicalTrials.gov ID: NCT03331432
Organization: University of Missouri-Columbia
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: NA
Conditions: Type 2 Diabetes Mellitus
Interventions: DIETARY_SUPPLEMENT: Tauroursodeoxycholic acid
DIETARY_SUPPLEMENT: Placebo
Lead sponsor: University of Missouri-Columbia (OTHER)
Enrollment: 8 participants
Eligibility: sex ALL, minimum age 20 Years, maximum age 65 Years
Accepts healthy volunteers: no
Start date: 2015-10-28
Completion date: 2018-02-14
Locations:
facility: University of Missouri
city: Columbia
state: Missouri
country: United States

Summary:
The purpose of the present study is to determine if use of dietary supplement tauroursodeoxycholic acid enhances insulin-stimulated leg blood flow and glucose disposal.
A Randomized Trial Evaluating the Efficacy and Safety of Control-IQ+ Technology in Adults With Type 2 Diabetes Using Basal-Bolus Insulin Therapy (2IQP)
Acronym: 2IQP
ClinicalTrials.gov ID: NCT05785832
Organization: Tandem Diabetes Care, Inc.
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: NA
Conditions: Type 2 Diabetes Treated With Insulin
Interventions: DEVICE: t:slim X2 insulin pump with Control-IQ+ technology and Dexcom G6 CGM
DEVICE: Standard Therapy plus continuous glucose monitoring (CGM)
Lead sponsor: Tandem Diabetes Care, Inc. (INDUSTRY)
Collaborators: Jaeb Center for Health Research
Enrollment: 319 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 
Accepts healthy volunteers: no
Start date: 2023-06-01
Completion date: 2024-09-24
Locations:
facility: Hoag Memorial Hospital Presbyterian
city: Newport Beach
state: California
country: United States
facility: Emory University School of Medicine
city: Atlanta
state: Georgia
country: United States
facility: Rocky Mountain Clinical Research
city: Idaho Falls
state: Idaho
country: United States
facility: Northwestern University
city: Chicago
state: Illinois
country: United States
facility: Baltimore VA Medical Center
city: Baltimore
state: Maryland
country: United States
facility: Boston Medical Center Corporation
city: Boston
state: Massachusetts
country: United States
facility: Henry Ford Health System
city: Detroit
state: Michigan
country: United States
facility: Mayo Clinic
city: Rochester
state: Minnesota
country: United States
facility: Icahn School of Medicine at Mt. Sinai
city: New York
state: New York
country: United States
facility: SUNY Upstate Medical University
city: Syracuse
state: New York
country: United States
facility: UHH Cleveland Medical Center
city: Cleveland
state: Ohio
country: United States
facility: Oregon Health & Science University
city: Portland
state: Oregon
country: United States
facility: University of Pennsylvania
city: Philadelphia
state: Pennsylvania
country: United States
facility: Texas Diabetes and Endocrinology, P.A.
city: Austin
state: Texas
country: United States
facility: University of Texas Southwestern
city: Dallas
state: Texas
country: United States
facility: Diabetes & Endocrine Treatment Specialists
city: Sandy City
state: Utah
country: United States
facility: University of Virginia
city: Charlottesville
state: Virginia
country: United States
facility: Rainier Clinical Research Center
city: Renton
state: Washington
country: United States
facility: University of Washington
city: Seattle
state: Washington
country: United States
facility: Lawson Health Research Institute
city: London
state: Ontario
country: Canada
facility: McGill University
city: Montreal
state: Quebec
country: Canada

Summary:
A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ+ technology in adults with type 2 diabetes using basal-bolus insulin therapy.
The Dual Role of Intramyocellular Lipids in Mediating Insulin Resistance: Assessing the Mechanisms of the Athlete's Paradox
Acronym: LIDDIA
ClinicalTrials.gov ID: NCT03314714
Organization: German Diabetes Center
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: NA
Conditions: Insulin Resistance, Diabetes
Lipid Metabolism Disorders
Interventions: PROCEDURE: Acute bout of endurance exercise
Lead sponsor: German Diabetes Center (OTHER)
Collaborators: Maastricht University
Enrollment: 100 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 69 Years
Accepts healthy volunteers: yes
Start date: 2017-04-03
Completion date: 2023-06-01
Locations:
facility: German Diabetes Center
city: Düsseldorf
state: North Rhine-Westphalia
country: Germany
facility: Maastricht University
city: Maastricht
country: Netherlands

Summary:
Accumulation of intramyocellular lipids (IMCLs) due to increased supply of fatty acids can induce defects in the insulin signaling cascade, causing skeletal muscle insulin resistance. However, the causes for muscle insulin resistance are not well understood. The association of elevated IMCLs and insulin resistance has been shown in obese humans and individuals with type 2 diabetes as well as several animal models of insulin resistance. Despite the strong relationship between IMCLs and insulin resistance, this suggested relationship disappears when well-trained endurance athletes are included into this consideration as this group is highly insulin sensitive. This metabolic enigma has been termed the 'athlete's paradox'. The aim of this project is to resolve the mechanisms contributing to the athlete's paradox.
Effect of Online Diabetic Foot Support Program (DiaFootSuP) and Care Kit on Diabetic Foot Care Outcomes: Randomized Controlled Trial
Acronym: DiaFootSuP
ClinicalTrials.gov ID: NCT06760416
Organization: Dokuz Eylul University
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Phases: NA
Conditions: Diabetes Mellitus
Diabetic Foot Ulcer
Diabetic Foot
Interventions: OTHER: Nursing Education
Lead sponsor: Merve GÃnbaAY (OTHER)
Collaborators: The Scientific and Technological Research Council of Turkey
Enrollment: 62 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 
Accepts healthy volunteers: no
Start date: 2024-11-01
Completion date: 2025-03-31
Locations:
facility: Dokuz Eylül University
city: Izmir
state: Buca
country: Turkey (Türkiye)

Summary:
The aim of this project is to examine the effects of the online diabetic foot support program (DiaFootSuP) and care kit applied to type 2 diabetic individuals who have previously had a diabetic foot ulcer on diabetic foot outcomes (diabetic foot knowledge level, foot care behavior level, foot care self-efficacy level, HbA1c, etc.).
Steroid-induced Diabetes Mellitus in Systemic Lupus Erythematosus (SLE) Patients
ClinicalTrials.gov ID: NCT04024306
Organization: Assiut University
Status: UNKNOWN
Study type: OBSERVATIONAL
Conditions: System; Lupus Erythematosus
Lead sponsor: Assiut University (OTHER)
Enrollment: 120 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 75 Years
Accepts healthy volunteers: no
Start date: 2022-09-01
Completion date: 2024-04-20
Locations:
facility: Assiut university hospital
city: Asyut
country: Egypt

Summary:
The aim of the study is to determine the prevalence of steroid-induced diabetes mellitus (SDM) among systemic lupus erythematosus (SLE) patients and identify and assess the associated risk factors .
A Single-blinded, Randomized, Placebo-controlled, Staggered-parallel, Escalating Single Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered SB756050 in Healthy Volunteers and in Subjects With Type 2 Diabetes Mellitus
ClinicalTrials.gov ID: NCT00607906
Organization: GlaxoSmithKline
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: PHASE1
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: SB-756050 immediate release capsule
DRUG: SB-756050 modified release capsule
DRUG: Placebo
Lead sponsor: GlaxoSmithKline (INDUSTRY)
Enrollment: 36 participants
Eligibility: sex ALL, minimum age 18 Years, maximum age 60 Years
Accepts healthy volunteers: yes
Start date: 2007-11-16
Completion date: 2008-03-10
Locations:
facility: GSK Investigational Site
city: Minneapolis
state: Minnesota
country: United States

Summary:
This study will use single escalating doses of SB756050 to assess safety, pharmacokinetics, and pharmacodynamics in healthy volunteers and in subjects with Type 2 Diabetes Mellitus.
The Evaluation of Laser Lancing Devices in Constructing Self-management Systems for Chronic Diseases in Adult Diabetes Patients
ClinicalTrials.gov ID: NCT05251506
Organization: Korea University Guro Hospital
Status: UNKNOWN
Study type: INTERVENTIONAL
Phases: NA
Conditions: Type 2 Diabetes
Interventions: DEVICE: laser lancing device or lancet for blood glucose level measurement
Lead sponsor: Korea University Guro Hospital (OTHER)
Collaborators: Korea Medical Device Development Fund
Enrollment: 80 participants
Eligibility: sex ALL, minimum age 20 Years, maximum age 79 Years
Accepts healthy volunteers: no
Start date: 2021-08-10
Completion date: 2022-12-31
Locations:
facility: Korea University medical center
city: Seoul
country: South Korea

Summary:
Self monitoring of blood glucose level is crucial in diabetes management, but currently available methods, lancet, have shown low compliance of self monitoring of blood glucose because of pain, keratinization of finger tip, secondary infection. The purpose of this study is evaluating laser lancing device which cause much less pain than lancet to increase compliance of blood sugar checking, and to establish self monitoring system for patients of chronic diseases.

The investigators recruit total of 80 type 2 diabetes patients who visit Korea University Medical center Guro and Ansan hospital. HbA1c level of subject is more than 6.5% and less than 8.5%, and their age is above 20 years and under 80 years. Subjects are randomly distributed in group A or B. Group A subjects use laser device to check blood glucose for 2 months, then take a month for wash out period. After wash out period, participants use lancet for following 2 months. Group B perform the process vice versa. The investigators evaluate the number of blood glucose measurement, HbA1c, diabetes distress scale, average pain score, average satisfaction score from each group.
Incretin-based Therapy in Late Preclinical Type 1 Diabetes
ClinicalTrials.gov ID: NCT02898506
Organization: University of Oulu
Status: COMPLETED
Study type: INTERVENTIONAL
Phases: PHASE2
Conditions: Type 1 Diabetes
Interventions: DRUG: Victoza®
DRUG: Placebo
Lead sponsor: University of Oulu (OTHER)
Collaborators: Oulu University Hospital
Tampere University Hospital
Turku University Hospital
Skane University Hospital
Enrollment: 13 participants
Eligibility: sex ALL, minimum age 10 Years, maximum age 30 Years
Accepts healthy volunteers: no
Start date: 2016-03
Completion date: 2021-06
Locations:
facility: University of Oulu and Oulu University Hospital, Dept of Children and Adolescents
city: Oulu
country: Finland
facility: University of Tampere and Tampere University Hospital
city: Tampere
country: Finland
facility: University of Turku and Turku University Hospital
city: Turku
country: Finland
facility: Lund University and Skåne University Hospital
city: Malmö
country: Sweden

Summary:
The objective of the trial is to study whether daily treatment with liraglutide improves endogenous insulin secretion, postpones progression to overt Type 1 diabetes, and is tolerable and safe in subjects aged 10-30 years, who are positive for multiple islet autoantibodies and have dysglycemia.